Vistagen Therapeutics, Inc. 8-K

What Happened
Vistagen Therapeutics (VTGN) filed an 8‑K on June 30, 2026 announcing topline results from its PALISADE‑4 Phase 3 trial of intranasal fasedienol for acute treatment of social anxiety disorder. The trial did not meet its primary endpoint: least squares (LS) mean change from baseline on the Subjective Units of Distress Scale (SUDS) was -9.5 (±1.7 SE) for fasedienol versus -11.4 (±1.7 SE) for placebo, a difference of 1.9 (p = 0.427). Secondary endpoints showed no treatment differences. Safety and tolerability were favorable and consistent with prior placebo‑controlled trials. The company also reported a nominally significant post‑hoc result in a predefined very severe subgroup (baseline Liebowitz Social Anxiety Scale [LSAS] ≥95).

Key Details

• Trial result (primary endpoint): SUDS LS mean change — fasedienol -9.5 (±1.7 SE) vs placebo -11.4 (±1.7 SE); difference 1.9, p = 0.427 (not statistically significant).
• Post‑hoc subgroup (LSAS ≥95, n=123): SUDS LS mean change — fasedienol -12.8 (±3.4 SE) vs placebo -3.7 (±3.4 SE); difference -9.1, p = 0.036 (nominal significance).
• Safety: Favorable and consistent with prior trials (no new safety signals reported).
• Corporate actions: Company issued a press release and presentation and will host a conference call/webcast on June 30, 2026; plans to meet with the FDA to discuss a potential regulatory path (including a possible single, multi‑dose Phase 3 with LSAS as primary endpoint). The company stated cash resources are expected to support operations into 2027.

Why It Matters
For investors, the key takeaway is that the lead Phase 3 study for fasedienol did not meet its primary efficacy endpoint, which is materially adverse for near‑term approval prospects based on these results. The positive post‑hoc finding in a very severe subgroup may inform discussions with the FDA and any future trial design, but post‑hoc results are exploratory and not a substitute for a successful prespecified primary endpoint. The company’s next steps—regulatory meetings, potential new pivotal trial design, and financial runway into 2027—will be important to watch for updates that could affect valuation and development timelines.